Skip to main content

Advertisement

Table 3 Univariate and multivariate analyses of variables associated with overall survival of patients with newly diagnosed metastatic colorectal cancer

From: Prognostic significance of the pre-chemotherapy lymphocyte-to-monocyte ratio in patients with previously untreated metastatic colorectal cancer receiving FOLFOX chemotherapy

Characteristic Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Gender 0.055   0.07
 Male 1 (reference)   1 (reference)  
 Female 0.804 (0.644–1.004)   0.812 (0.648-1.017)  
Age (years) 0.567   0.199
 <65 1 (reference)   1 (reference)  
 ≥65 1.070 (0.849–1.347)   0.842 (0.647–1.095)  
ECOG performance status 0.005   <0.001
 <2 1 (reference)   1 (reference)  
 ≥2 1.388 (1.103–1.747)   1.620 (1.244–2.111)  
Site of primary tumor 0.974   0.938
 Colon 1 (reference)   1 (reference)  
 Rectum 1.004 (0.806–1.250)   1.009 (0.809–1.257)  
No. of metastatic sites 0.002   0.065
 ≤2 1 (reference)   1 (reference)  
 >2 1.417 (1.135–1.769)   1.252 (0.986–1.589)  
Tumor differentiation <0.001   0.002
 Well or moderate 1 (reference)   1 (reference)  
 Poor 1.736 (1.385–2.176)   1.484 (1.159–1.901)  
Pre-chemotherapy ALC (×109/L) 0.121   0.391
 <2.70 1 (reference)   1 (reference)  
 ≥2.70 0.841 (0.676–1.047)   0.884 (0.668–1.171)  
Pre-chemotherapy AMC (×109/L) <0.001   <0.001
 <0.55 1 (reference)   1 (reference)  
 ≥0.55 1.514 (1.204–1.903)   1.703 (1263–2.296)  
Pre-chemotherapy LMR <0.001   0.004
 <3.11 1 (reference)   1 (reference)  
 ≥3.11 0.568 (0.453–0.712)   0.662 (0.501–0.875)  
  1. Abbreviations as in Tables 1 and 2